These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 8849237

  • 1. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.
    Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner SJ.
    Antimicrob Agents Chemother; 1996 Apr; 40(4):839-45. PubMed ID: 8849237
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Steckelberg JM.
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [Abstract] [Full Text] [Related]

  • 3. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
    Jones RN, Johnson DM, Erwin ME.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):720-6. PubMed ID: 8851600
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
    Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
    [Abstract] [Full Text] [Related]

  • 6. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.
    Kaatz GW, Seo SM.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):799-801. PubMed ID: 8851617
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
    Ueda Y, Sunagawa M.
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
    [Abstract] [Full Text] [Related]

  • 8. In vitro activities in new oxazolidinone antimicrobial agents against enterococci.
    Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC.
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1745-7. PubMed ID: 8807077
    [Abstract] [Full Text] [Related]

  • 9. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.
    Ford CW, Hamel JC, Wilson DM, Moerman JK, Stapert D, Yancey RJ, Hutchinson DK, Barbachyn MR, Brickner SJ.
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1508-13. PubMed ID: 8726028
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The in-vitro activity of linezolid (U-100766) and tentative breakpoints.
    Wise R, Andrews JM, Boswell FJ, Ashby JP.
    J Antimicrob Chemother; 1998 Dec; 42(6):721-8. PubMed ID: 10052894
    [Abstract] [Full Text] [Related]

  • 12. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.
    Jorgensen JH, McElmeel ML, Trippy CW.
    Antimicrob Agents Chemother; 1997 Feb; 41(2):465-7. PubMed ID: 9021209
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ, Hershberger E, Moldovan T, Grucz RG.
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
    [Abstract] [Full Text] [Related]

  • 14. Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709.
    Brumfitt W, Hamilton-Miller JM.
    Diagn Microbiol Infect Dis; 1992 Apr; 15(7):621-5. PubMed ID: 1424519
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.
    Neu HC, Novelli A, Saha G, Chin NX.
    Antimicrob Agents Chemother; 1988 Apr; 32(4):580-3. PubMed ID: 3377467
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.
    Mulazimoglu L, Drenning SD, Yu VL.
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2428-30. PubMed ID: 8891159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.